Physician profile
Brian Francis
NPI 1780663971
$9,757.09
in general payments reported to CMS, 2019-2025
45 companies · $814 in 2025
The $814 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,057 · 2020: $1,160 · 2021: $1,971 · 2022: $1,662 · 2023: $1,081 · 2024: $1,011 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,906.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,208.71 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $1,124.80 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $927.12 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $773.61 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $618.59 | 2021-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $475.14 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $459.68 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Sanofi-Aventis U.S. LLC | $429.93 | 2019-2023 | |
| Amgen INC. | $411.88 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $380.52 | 2021-2025 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $316.60 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $302.62 | 2021-2025 | |
| Allergan, INC. | $256.35 | 2019-2021 | |
| Amarin Pharma, INC. | $241.50 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $207.97 | 2023-2024 | Gemtesa |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Francis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.